The dangers of new oral Covid drug Molnupiravir

Coronavirus, Healthcare, Molnupiravir, Side Effects

“The FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval. My misgivings are founded on two key concerns. The first is the drug’s potential mutagenicity, and the possibility that its use could lead to birth defects or cancerous tumors. The second is a danger that is far greater and potentially far deadlier: the drug’s potential to supercharge SARS-CoV-2 mutations and unleash a more virulent variant upon the world.”

William Haseltine at


UK approves oral Covid drug Molnupiravir for use


** This post was originally published on November 3, 2021 **